Happy to announce the promising results of our phase IIb clinical trial evaluating the efficacy of denosumab 120 mg among adults with Langerhans cell histiocytosis (LCH). We showed a response rate of 80%.
Full paper can be accessed here: pubmed.ncbi.nlm.nih.gov/37073626/